Eylea vs Miebo
A side-by-side look at two eye health medications advertised on TV. Informational only — not medical advice.
| US Eylea | US Miebo | |
|---|---|---|
| Generic name | aflibercept | perfluorohexyloctane |
| Drug class | VEGF Inhibitor (Eye Injection) | Semifluorinated Alkane (Eye Drop) |
| Treats | Wet macular degeneration, diabetic eye disease | Dry eye disease |
| Category | Eye Health | Eye Health |
| Manufacturer | Regeneron | Bausch + Lomb |
| Year approved | 2011 | 2023 |
| FDA warning | No boxed warning | No boxed warning |
| Est. TV ad spend | $90M | — |
| Common side effects | Eye floaters, Eye pain, Increased eye pressure, Bleeding in the eye | Blurred vision, Eye redness, Temporary discomfort on application |
Frequently asked questions
Is Eylea or Miebo better?
Neither is universally "better." Eylea (aflibercept) and Miebo (perfluorohexyloctane) are both used for eye health, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Eylea and Miebo?
Eylea is a VEGF Inhibitor (Eye Injection) made by Regeneron, while Miebo is a Semifluorinated Alkane (Eye Drop) made by Bausch + Lomb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Eylea has the larger estimated TV advertising budget of the two.